Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 8, 2013
- Accepted in final form April 24, 2013
- First Published July 12, 2013.
Article Versions
- Previous version (July 12, 2013 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Amit Bar-Or, MD,
- Mark S. Freedman, MD,
- Marcelo Kremenchutzky, MD,
- Françoise Menguy-Vacheron, PhD,
- Deborah Bauer, MS,
- Stefan Jodl, MD,
- Philippe Truffinet, MD,
- Myriam Benamor, MD,
- Scott Chambers, PhD and
- Paul W. O’Connor, MD
- Amit Bar-Or, MD,
Diogenix, Advisor, Scientific Board, 2008- Ono Pharmacia, Advisor, Scientific Board, 2008- Receptos, Advisor, Scientific Board, 2011 - Roche, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Guthy Jackson Greater Good Foundation, NMO Research and Clinical Care Consortium, Scientific Advisor, 2009-
NONE
NONE
Neurology, Editorial Board Member, 2008- Clinical and Experimental Neuroimmunology, Editorial Board Member, 2010 -
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Novartis 2. EMD Serono 3. Amplimmune
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mark S. Freedman, MD,
Actelion, sanofi-aventis/Genzyme, Novartis, Merck Serono, Bayer, BiogenIdec, Roche, Celgene, Opexa, Teva
NONE
Merck Serono, Novartis, Sanofi-Aventis/Genzyme
J Neurol Sci Multiple Sclerosis Multiple Sclerosis International Int J MS Care
NONE
NONE
NONE
Celgene, Opexa, Novartis, Sanofi, Bayer, Merck Serono, Kirin, BiogenIdec
NONE
NONE
NONE
Bayer, Genzyme
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marcelo Kremenchutzky, MD,
NONE
NONE
Funding for travel or speaker honoraria from (1) Biogen, (2) Bayer, (3) Teva, (4) Genzyme - sanofi, (5) Novartis, (6) serono
NONE
NONE
NONE
NONE
(1) Biogen, (2) Bayer, (3) Teva, (4) Genzyme - Sanofi, (5) Novartis, (6) Serono
NONE
NONE
NONE
(1) Genzyme, (2) Cell Gene, (3) Biogen, (4) Bayer, (5) Teva, (6) Sanofi, (7) Novartis, (8) Serono
(1) CIHR, co-investigator, from: 2011-04-01 to: 2016-03-31
NONE
(1) MS Society of Canada
NONE
NONE
NONE
NONE
NONE
NONE
- Françoise Menguy-Vacheron, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
1) Employee of Genzyme, a Sanofi company , Clinical research director in clinical pharmacology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Deborah Bauer, MS,
NONE
NONE
NONE
NONE
NONE
NONE
(1) Sanofi, Biostatistician
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefan Jodl, MD,
NONE
NONE
NONE
NONE
NONE
NONE
Sanofi, Clinical Study Director (CSD)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Philippe Truffinet, MD,
NONE
NONE
NONE
NONE
NONE
NONE
Genzyme/Sanofi, Clinical Research Director
NONE
NONE
NONE
NONE
Salary as employee
NONE
NONE
NONE
Stocks, as employee
NONE
NONE
NONE
NONE
NONE
- Myriam Benamor, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Scott Chambers, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Employee of Fishawack Communications Ltd, contracted to provide editorial services to Sanofi, funded by Genzyme, a Sanofi company.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paul W. O’Connor, MD
Novartis Fingolimod Steering Committee--member--2007-present Teriflunomide Steering Committee ( sanofi aventis)--chairman--2006-present Bayer BEYOND study steering committee--chairman--2007-2009 BRAVO (laquinimod) study DMC--chairman--2007-present Genentech advisory board--member Roche advisory board Receptos advisory board Actelion advisory board
NONE
1 Biogen Idec-ECTRIMS meeting Dusseldorf--2009--presentations of data from two studies 2 Teva--Meeting in London--advise and present data on safety of MS drugs--2009 3 Advisory board meeting in Montreal 2010 4 Advisory board meeting in Toronto 2013
1 MS Journal. Editorial advisory board. July 2012--March 2013
NONE
NONE
NONE
Biogen Idec consultant 2007-2012 Actelion consultant 2010 Bayer Consultant 2007-2009 EMD Serono Consultant 2009-11 Teva Consultant 2007-2013 Genentech Consultant 2007-2008 Sanofi Genzyme Consultant 2002-2013 Novartis Consultatn 2005-2013 Warburg Pincus Consultant 2009
NONE
NONE
NONE
1 Bayer--study grant support for BEYOND study--2006-8 2 Novartis--study grant support for FREEDOMS, TRANSFORMS and INFORMS study--2006-2012 3 BIOMS--study grant support 2006-9 4 Sanofi Aventis-grant supprot for TEMSO, phase 2 , CIS and nerispirdine studies 5 ROCHE; grant supprot for phase 2 OCRELIZUMAB study 6 Biogen Idec: grant support for ASCEND and JEMS study 7 Roche grant support for OPERA and ORATORIO studies 8 Novartis support for INFORMS study of PPMS
NONE
NONE
National Scientific and Clinical Advisor to to the MS Society of Canada. 2008-2013 (ongoing)
NONE
NONE
NONE
NONE
NONE
NONE
- From McGill University (A.B.-O.), Montreal, Quebec, Canada; University of Ottawa and the Ottawa Hospital Research Institute (M.S.F.), Ottawa, Ontario, Canada; Western University (M.K.), London, Ontario, Canada; Genzyme, a Sanofi company (F.M.-V., P.T.), Chilly Mazarin, France; Sanofi (D.B.), Bridgewater, NJ; Kleinmachnow (S.J.), Germany; Sanofi (M.B.), Chilly Mazarin, France; Fishawack Communications Ltd. (S.C.), Abingdon, UK; and University of Toronto (P.W.O.), Toronto, Ontario, Canada.
- Correspondence to Dr. Bar-Or: amit.bar-or{at}mcgill.ca
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosisLudwig Kappos, Matthias Mehling, Rafael Arroyo et al.Neurology, January 30, 2015 -
Article
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosisThe VELOCE studyAmit Bar-Or, Jonathan C. Calkwood, Cathy Chognot et al.Neurology, July 29, 2020 -
Article
Impact of siponimod on vaccination response in a randomized, placebo-controlled studyMike Ufer, Kasra Shakeri-Nejad, Anne Gardin et al.Neurology: Neuroimmunology & Neuroinflammation, September 14, 2017 -
Null Hypothesis
Seasonal influenza vaccine and Guillain-Barré syndromeA self-controlled case series studyClémence Grave, Pauline Boucheron, Jérémie Rudant et al.Neurology, February 25, 2020